Stocks of Masimo Corporation (NASDAQ:MASI) traded higher last session on Wall Street, up 0.70% to $143.02.
As we calculate the median target price by taking the range between a high of $180.00 and a low of $135.00, we find $155.00. Given the previous closing price of $142.03, this indicates a potential upside of 9.13 percent. MASI stock price is now 4.71% away from the 50-day moving average and -0.07% away from the 200-day moving average. The market capitalization of the company currently stands at $7.28B.
Brokers who have rated the stock have averaged $155.67 as their price target over the next twelve months.
With the price target of $180, Jefferies recently initiated with Buy rating for Masimo Corporation (NASDAQ: MASI). On September 15, 2022, Wolfe Research Upgraded its previous ‘Peer Perform’ rating to ‘Outperform’ on the stock keeping its target price maintained at $165, while ‘Loop Capital’ rates the stock as ‘Buy’.
In other news, KIANI JOE E, CEO and Chairman of the Board bought 31,994 shares of the company’s stock on Nov 14. The stock was bought for $3,967,010 at an average price of $123.99. Upon completion of the transaction, the CEO and Chairman of the Board now directly owns 39,778 shares in the company, valued at $5.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11, CEO and Chairman of the Board KIANI JOE E bought 7,784 shares of the business’s stock. A total of $1,006,255 was incurred on buying the stock at an average price of $129.27. This leaves the insider owning 7,784 shares of the company worth $1.11 million. Insiders disposed of 16,447 shares of company stock worth roughly $2.35 million over the past 1 year. A total of 8.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MASI stock. A new stake in Masimo Corporation shares was purchased by POLITAN CAPITAL MANAGEMENT LP during the first quarter worth $664,881,000. NATIONAL BANK OF CANADA /FI/ invested $29,090,000 in shares of MASI during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Masimo Corporation valued at approximately $29,046,000. HAWK RIDGE CAPITAL MANAGEMENT LP acquired a new stake in MASI for approximately $25,645,000. ING GROEP NV purchased a new stake in MASI valued at around $21,453,000 in the second quarter. In total, there are 631 active investors with 90.70% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $142.99 for Masimo Corporation (NASDAQ: MASI). During the past 12 months, Masimo Corporation has had a low of $108.89 and a high of $299.78. As of last week, the company has a debt-to-equity ratio of 0.77, a current ratio of 2.10, and a quick ratio of 1.30. The fifty day moving average price for MASI is $136.43 and a two-hundred day moving average price translates $142.71 for the stock.
The latest earnings results from Masimo Corporation (NASDAQ: MASI) was released for Jul, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at $1.35, beating analysts’ expectations of $1.2 by 0.15. This compares to $1.00 EPS in the same period last year. The net profit margin was 9.80% and return on equity was 12.20% for MASI. The company reported revenue of $549.3 million for the quarter, compared to $307.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.69 percent. For the current quarter, analysts expect MASI to generate $533.44M in revenue.
Masimo Corporation(MASI) Company Profile
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.